Mar 25 |
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
|
Mar 6 |
Retail investors invested in BeyondSpring Inc. (NASDAQ:BYSI) up 125% last week, insiders too were rewarded
|
Feb 26 |
BeyondSpring regains Nasdaq compliance as price surges above $1
|
Feb 26 |
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
|
Jan 11 |
BeyondSpring gets Nasdaq delinquency notice
|
Jan 10 |
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
|
Dec 18 |
BeyondSpring receives Nasdaq notice regarding minimum bid price requirements
|
Nov 7 |
BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibi...
|
Oct 31 |
BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
|
Oct 30 |
BeyondSpring regains compliance with Nasdaq minimum bid price rule
|